I know everyone wants to compare the two because Exubera was an inhaled insulin, but they aren't competing head to head. different time different situation. The reason why Afrezza is ridiculed is because of Exubera's failure. You know the two are nothing alike and you know that SNY has deliberately planned a calculated slow launch for Afrezza. So why ignore those facts? You seem to think SNY doesn't know what they are doing. It is too early to say if Afrezza is a failure. And comparing it to Exubera is disingenuous.
News 
Market Data 
Discover 
